Price$9.89+0.02 (+0.20%)
01:30 PM07:45 PM
News · 26 weeks50-75%
2025-11-022026-04-26
Mix3690d
- Insider18(50%)
- SEC Filings10(28%)
- Other5(14%)
- Earnings2(6%)
- Offering1(3%)
Latest news
25 items- SECSEC Form DEFA14A filed by Arvinas Inc.DEFA14A - ARVINAS, INC. (0001655759) (Filer)
- SECSEC Form DEF 14A filed by Arvinas Inc.DEF 14A - ARVINAS, INC. (0001655759) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Arvinas Inc.SCHEDULE 13G/A - ARVINAS, INC. (0001655759) (Subject)
- INSIDERSEC Form 4 filed by Berkowitz Noah4 - ARVINAS, INC. (0001655759) (Issuer)
- SECArvinas Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - ARVINAS, INC. (0001655759) (Filer)
- PRArvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days– ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson's disease and progressive supranuclear palsy – – ARV-102 was well tolerated across all dose levels following 28 days of once-daily dosing – – Data support further development of ARV-102 in additional neurodegenerative diseases characterized by lysosomal dysfunction, including progressive supranuclear palsy, a rapidly progressing and devastating tauopathy – – Data presented during an oral session at the Alzheimer's and Parkinson's Diseases and Related Neurological Disorders Conference – NEW HAVEN, Conn., March 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology
- SECSEC Form 144 filed by Arvinas Inc.144 - ARVINAS, INC. (0001655759) (Subject)
- INSIDERAmendment: President and CEO Teel Randy was granted 147,179 shares, increasing direct ownership by 98% to 296,875 units (SEC Form 4)4/A - ARVINAS, INC. (0001655759) (Issuer)
- PRArvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders– Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson's disease – NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that data from a Phase 1 clinical trial of ARV-102 in participants with Parkinson's disease (PD) will be presented at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026), March 17-21, 2026, in Copenhagen, Denmark. ARV-102 is Arvinas' investigational, orally bio
- INSIDERDirector Morrison Briggs bought $268,070 worth of shares (20,000 units at $13.40), increasing direct ownership by 26% to 96,021 units (SEC Form 4)4 - ARVINAS, INC. (0001655759) (Issuer)
- INSIDERVP, Chief Accounting Officer Loomis David K was granted 12,420 shares, increasing direct ownership by 42% to 42,112 units (SEC Form 4)4 - ARVINAS, INC. (0001655759) (Issuer)
- INSIDERChief Scientific Officer Cacace Angela M was granted 45,000 shares, increasing direct ownership by 30% to 192,623 units (SEC Form 4)4 - ARVINAS, INC. (0001655759) (Issuer)
- INSIDERChief Medical Officer Berkowitz Noah was granted 45,000 shares, increasing direct ownership by 27% to 208,938 units (SEC Form 4)4 - ARVINAS, INC. (0001655759) (Issuer)
- INSIDERChief Financial Officer Saik Andrew was granted 45,000 shares, increasing direct ownership by 28% to 204,267 units (SEC Form 4)4 - ARVINAS, INC. (0001655759) (Issuer)
- INSIDERPresident and CEO Teel Randy was granted 147,791 shares, increasing direct ownership by 99% to 297,487 units (SEC Form 4)4 - ARVINAS, INC. (0001655759) (Issuer)
- INSIDERDirector Houston John G sold $466,154 worth of shares (35,297 units at $13.21), decreasing direct ownership by 3% to 1,122,183 units (SEC Form 4)4 - ARVINAS, INC. (0001655759) (Issuer)
- INSIDERChief Accounting Officer Loomis David K sold $13,473 worth of shares (1,108 units at $12.16), decreasing direct ownership by 4% to 29,692 units (SEC Form 4)4 - ARVINAS, INC. (0001655759) (Issuer)
- INSIDERChief Scientific Officer Cacace Angela M sold $43,885 worth of shares (3,609 units at $12.16), decreasing direct ownership by 2% to 147,623 units (SEC Form 4)4 - ARVINAS, INC. (0001655759) (Issuer)
- INSIDERPresident and CEO Teel Randy sold $58,198 worth of shares (4,786 units at $12.16), decreasing direct ownership by 3% to 149,696 units (SEC Form 4)4 - ARVINAS, INC. (0001655759) (Issuer)
- SECSEC Form S-8 filed by Arvinas Inc.S-8 - ARVINAS, INC. (0001655759) (Filer)
- SECSEC Form 10-K filed by Arvinas Inc.10-K - ARVINAS, INC. (0001655759) (Filer)
- SECArvinas Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ARVINAS, INC. (0001655759) (Filer)
- PRArvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update– Company entering 2026 with the potential to deliver multiple value-driving milestones, including data readouts from ARV-102, ARV-806, and ARV-393, with cash runway into second half of 2028 – – ARV-102 (LRRK2) Phase 1 clinical data in patients with Parkinson's disease accepted for oral presentation at AP/PD Conference in March 2026 – – Clinical data from ARV-806 (KRAS G12D) and ARV-393 (BCL6) on track for presentations in 2026 – – Phase 1 trial in healthy volunteers initiated with polyQ-AR degrader ARV-027; first immuno-oncology PROTAC HPK1 degrader, ARV-6723, on track to initiate Phase 1 trial in mid-2026 – – Randy Teel, Ph.D., appointed President, Chief Executive Officer, and
- PRArvinas to Participate in Upcoming Investor ConferencesNEW HAVEN, Conn, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in four upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Tuesday, March 3. Management will participate in a fireside chat, available here, at 1:10 p.m. ET.Leerink Global Healthcare Conference on Monday, March 9. Management will participate in a fireside chat, available here, at 4:20 p.m. ET.Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10. Management will participate in a fireside chat, available here, at
- INSIDERPresident and CEO Teel Randy sold $52,352 worth of shares (4,403 units at $11.89), decreasing direct ownership by 3% to 154,482 units (SEC Form 4)4 - ARVINAS, INC. (0001655759) (Issuer)
ARVN FAQ
7 questionsWhat does Arvinas Inc. do?
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The...Where does ARVN stock trade?
Arvinas Inc. (ARVN) is listed on NASDAQ.What sector and industry is ARVN in?
Arvinas Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Arvinas Inc. go public?
Arvinas Inc. (ARVN) completed its IPO in 2018.What are analysts saying about ARVN?
Arvinas Inc. has had 8 recent analyst actions on file. The most recent action was from Citigroup: Buy with a $1500.00 price target on 2026-01-06. Recent price targets range from $600.00 to $1600.00.What companies are similar to ARVN?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ARVN side-by-side with any of them on Quantisnow.How can I track ARVN on Quantisnow?
Quantisnow aggregates Arvinas Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARVN to receive live email and push alerts on every new disclosure.